newsfilter
← Latest News
PR Newswire·

Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026

  • Q32 Bio Inc. announced that late-breaking oral and poster presentations at the EADV Congress in Vienna (Sept 30 – Oct 3, 2026) will feature 36-week results & initial 16-week off-drug findings from Part B of the SIGNAL-AA Phase 2a trial.
  • The trial evaluates bempikibart, a fully human anti-IL-7Rα antibody designed to block IL-7 & TSLP signaling, in patients with severe or very severe alopecia areata.
  • Oral presentation "LB-375" titled "Bempikibart, a novel IL-7Rα antibody, produces hair regrowth that persists off treatment..." is scheduled for Wednesday, Sept 30, 2026, at 3:15 p.m. CEST in Hall A.
  • Presenter for the oral session is Arash Mostaghimi, MD, MPA, MPH, Associate Professor at Brigham and Women's Hospital, Harvard Medical School.
  • Poster presentation "AS-726" titled "Preliminary Results for an Open-label Phase 2a Trial (SIGNAL-AA Part B)..." is scheduled for Wednesday, Sept 30, 2026, at 7:00 a.m. CEST in the Poster Area.
  • Both presentations will be available in the "Presentations and Publications" section of the Q32 Bio website following the formal EADV event.
  • CEO Jodie Morrison stated the presentations underscore the company's commitment to bringing a differentiated therapeutic to patients with limited current treatment options.
  • Approximately 700,000 people in the United States live with alopecia areata, a condition with life-altering impacts & limited treatment options.
  • Q32 Bio is advancing bempikibart (ADX-914) in an ongoing Phase 2 program targeting the IL-7 & TSLP pathways implicated in T cell-mediated autoimmune diseases.
  • The press release includes standard forward-looking statements regarding risks, uncertainties, & potential outcomes of the clinical trials & business operations.